West Egg has become Fleet Street

West Egg has become Fleet Street.Tamara Sim seems like Perez Hilton mind in Carey Bradshaw body while Honor Tait could easily be a shallow fusion of Maggie Thatcher http://ugky.in/2d0 and Christoper Hitchens. An antagonistic Nick Carraway and a curmudgeonly but academic Jay Gatsby.I underestimated both protagonists for most of the story, but Honor emotional vortex dragged http://lx.pe/b84b me under, and that what I remember about the book.I say that The Spoiler comes within an http://flsd.co/xhz6 inch of being the Gatsby of journalism only because there are some basic flaws within what is, otherwise, an enjoyable and worthwhile read. The protagonists lack depth until the http://gentil.vc/2c7bq second half of the book and the supporting characters are, for the most part, stereotypical to the point of cliche. It jarring at first, but The Spoiler works less as an attempt http://gf10.com.br/url/zbv at high culture and more as an attempt at a caricature of the print media in http://gid.me/gsl the moment before it was transformed by the Internet. Like all effective communication, good writing http://mlr.me/w0h could be said to occur when the gap between 'what one desires to say and http://redir.cc/1em what one is constrained to mean' is negligible http://infom.us/2s2 or almost non existent; and though the scope to edit, rewrite and re read may http://norw.in/ipflr add a http://w.tl/58r4 certain degree of effectiveness to writing, the words of Nathaniel Hawthorne effectively echo the real challenge involved in the task 'Easy reading is damned hard writing'.MannKind received its CRL on January 20 of this year for Afrezza, its own human http://slyp.in/5xpi insulin formulation but in an inhalable powder form. The FDA's CRL for Afrezza http://www.miniurl.nu/18mk indicated concerns pertaining to the use of in vitro performance data and clinical pharmacology http://www.domeny.findit.pl/-by data to link MannKind's next generation inhaler to the Phase III trials conducted http://j34.co/cg0w using its MedTone inhaler. There were other more easily http://craigslistinfolinks.com/1ivd addressed concerns in http://l.hol.st/lt5f the CRL, but determining equivalency http://notgemerit.gatewayy.net/ocb between the http://nnx.me/z636 two devices was of enough concern to merit two additional trials by MannKind. http://alumnice.co/6cp8 Trials would need to be conducted on http://kleine-url.de/12t- type 1 and type 2 diabetes patients using the next generation inhaler in at least one of the trials for side by side comparisons with the MedTone inhaler. As per http://likesh.it/iXv their May 9 press release http://mtndew.me/6a64 discussing 1Q 2011 http://torching.us/2q0 financials, MannKind had not initiated the trials but http://lqrs.me:/i946 did indicate that they had their End of Review meeting with the FDA in which http://hishort.com/x8dx2 they received http://u.mandib.com/13k1e additional advice about the trials' designs and will initiate the trials once a final protocol is agreed upon. With a financial reserve in the form of cash, cash equivalents and marketable securities of $47.5 million as of http://teil.cc/XN8a7 March 31, 2011, MannKind will also need additional financing before its trials complete as they burned through $38.1 million in 1Q. Depending on the http://nwspprs.com/nszf trials' designs, MannKind will likely beat Biodel to the http://pa.ikli.in/1iol NDA, even with the accelerated time frame Biodel has implemented, but they may have a more difficult time financially getting there.